However, we provided evidence that inhibition of de novo protein synthesis by CHX failed to have overt effect on class I/II HDACI‐induced suppression of AKT phosphorylation in prostate cancer cells and the drug effect appears to be an immediate event (30 min post‐treatment). This evidence concerns the gene AKT1 and prostate carcinoma.